Print Friendly, PDF & Email

NCT/Study#

NCT03487666 /

2017-1535-CA209-8CL

OXEL: A Pilot Study Of Immune Checkpoint Or Capecitabine Or Combination Therapy As Adjuvant Therapy For Triple Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy

DISEASE GROUP:

Breast Cancer Clinical Trials

current phase:

Phase II

STUDY STATUS:

Accepting Patients

Location:

Hackensack, NJ

For More information:

Call 201-518-3587